FDA approves first oral GLP-1 for obesity

The US Food and Drug Administration (FDA) has approved orforglipron, marketed under the brand name Foundayo by Eli Lilly, for the treatment of obesity. This marks a significant milestone: orforglipron is the first oral GLP-1 receptor agonist to receive approval specifically for weight management, eliminating the need for subcutaneous injection that has been a barrier to adherence for many patients.

Approval basis

The approval was supported by data from the ACHIEVE Phase 3 clinical trial programme. The ACHIEVE-1 trial, published in the New England Journal of Medicine, demonstrated that orforglipron achieved weight loss comparable to injectable GLP-1 agonists. Patients receiving the highest dose achieved mean weight reductions in the range of 12–15% over the trial period, positioning orforglipron as a clinically meaningful oral alternative to injectable semaglutide and tirzepatide.

Why this matters for peptide research

Orforglipron is a small-molecule GLP-1 receptor agonist rather than a peptide itself, but its development trajectory and approval have direct implications for the broader peptide therapeutics field:

  • Oral delivery paradigm: The success of an oral GLP-1 agonist validates oral bioavailability as an achievable goal for incretin-based therapies, which may influence research directions for other peptide candidates.
  • Competitive landscape: Foundayo enters a market currently dominated by injectable semaglutide (Wegovy) and tirzepatide (Mounjaro/Zepbound). Its oral route of administration could capture patients who discontinue injectable therapy.
  • Dosing convenience: Unlike semaglutide's oral formulation (Rybelsus), which requires strict fasting conditions, orforglipron can be taken without food restrictions, a practical advantage.

UK and European status

Orforglipron has not yet received marketing authorisation from the MHRA or the European Medicines Agency (EMA). Eli Lilly is expected to submit for regulatory approval in the UK and EU. If approved, orforglipron would face NICE appraisal for NHS use — a process that typically takes 6–18 months after marketing authorisation.

UK researchers should note that orforglipron remains unlicensed in the UK. The compound's classification would shift to a Prescription-Only Medicine (POM) upon MHRA approval.

Safety profile

The adverse event profile observed in the ACHIEVE trials was consistent with the GLP-1 receptor agonist class: gastrointestinal effects including nausea, diarrhoea, vomiting, and constipation were the most commonly reported events. Discontinuation rates due to adverse events were modest and generally lower than those seen with some injectable counterparts.

— This article is for research and educational purposes only. Orforglipron is not licensed for use in the UK. Foundayo is a prescription medicine in the United States.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.